Analysis of the main differences between lnavolisib and apelvis-Piqray

With the continuous development of precision medicine,the role of the PI3K pathway in various tumors has received increasing attention, especially in the field of hormone receptor-positive (HR+), HER2-negative breast cancer. PIK3CA gene mutation is one of the most common molecular abnormalities. It activates the PI3K-AKT-mTOR pathway and promotes tumor growth, invasion and resistance to treatment. Based on in-depth research on this target, a series of PI3K inhibitors have entered clinical trials, including the marketed Alpelisib-Piqray and the investigational drug Inavolisib (code-named GDC-0077) that has attracted much attention in recent years. Although both are positioned to selectively inhibit PI3Kα, they have many differences in molecular structure, mechanism of action, tolerance, indication expansion potential, and combination strategies. These differences are of great significance for clinicians to formulate individualized treatment strategies.

1. From a mechanism of action point of view, Apelvis is the first PI3Kα selective inhibitor to obtain regulatory approval. It was originally developed by Novartis. It mainly acts on HR+/HER2- breast cancer patients with PIK3CA mutations and is usually used in combination with fulvestrant. It blocks downstream signaling pathways by inhibiting the activity of PI3Kα isoforms, thereby inhibiting the growth and proliferation of cancer cells. In contrast, inaliset is a more advanced PI3Kα inhibitor developed by Genentech and has been finely optimized in mechanism. Studies have shown that inaliset not only has the ability to highly selectively inhibit PIK3CA mutants, but also shows less impact on wild-type PI3K activity at the molecular level, meaning that it may have a lower side effect burden. More importantly, inaliset has the ability to promote the degradation of mutant PIK3CA protein. This additional mechanism may give it a more durable and thorough anti-tumor effect, thus distinguishing it from the pure enzyme inhibition mode of traditional PI3K inhibitors.

2. From the perspective of clinical application, Apelvis is a marketed drug with relatively clear main indications. It is mainly used forHR+/HER2- breast cancer patients who have received endocrine therapy in the past and have PIK3CA mutations. The drug has been included in the standard treatment path in the European and American markets, but its widespread application is still limited by side effects management. In particular, metabolic and immune-related adverse reactions such as hyperglycemia, rash, and diarrhea are relatively common. Therefore, patient screening and monitoring requirements are high in clinical practice. Although inarisep is still in the clinical research stage, there are already multiple international multi-center trials exploring its applicability in different tumor types, not only limited to breast cancer, but also lung cancer, endometrial cancer, etc. More importantly, its potential as a combination treatment platform continues to be amplified, especially when combined with CDK4/6 inhibitors such as palbociclib, it has shown positive signals and is expected to bring breakthroughs to endocrine therapy-resistant populations.

Three. From the perspective of tolerability and safety, the differences in mechanisms directly lead to different clinical experiences. Apelix acts on both mutant and wild-typePI3Kα, therefore, easily interferes with normal cell metabolism, thereby triggering significant hyperglycemic events, which is a major difficulty in its use. Although there are corresponding prevention and control strategies, such as dietary management and the use of antidiabetic drugs, there are still limitations for patients with a history of diabetes or insulin resistance. In contrast, inalisate has less effect on wild-type PI3K and can guide the selective degradation of mutant proteins. It can theoretically reduce the occurrence of adverse events and improve patients' treatment compliance. Preliminary research also shows that the metabolic abnormalities caused by it are relatively mild, and the incidence of non-specific reactions such as skin toxicity is also slightly lower.

Four. Development strategy and indication expansion path, the success of Apelvis has established a preliminary paradigm forPI3K targeted therapy, but its scope of action is currently mainly limited to the field of breast cancer. Inalise has been regarded as a "next-generation PI3Kα inhibitor" from the early stages of design. Developers are actively exploring its combination strategy after multi-line treatment, and even trying to introduce the drug in the early stages of endocrine therapy in order to delay the occurrence of drug resistance through earlier intervention. In addition, the prospects of inaliside in brain metastasis indications have also received widespread attention. In particular, whether brain lesions related to PIK3CA mutations can be effectively controlled by oral targeted drugs is one of the focuses of current research.

Five. In terms of drug acquisition, Apelvis has been launched in the European, American and Indian markets, and has been covered by medical insurance in some countries and regions. However, it has not yet been launched in mainland China, so domestic patients usually need to obtain the drug through overseas drug purchase platforms. Relatively speaking, as a drug under development, inaliset can only be qualified for use through clinical trial channels or specific projects. There is no formal channel for ordinary patients to obtain this drug. However, with the advancement of its Phase III clinical trials, the future market prospects are relatively optimistic, and it is expected to be registered in multiple international markets simultaneously.

Reference materials:https://www.piqray.com/